British Journal of Diabetes最新文献_第6页

Life of RD Lawrence (1892-1968) - pioneering doctor and survivor of diabetes RD Lawrence（1892-1968）的一生-糖尿病的先驱医生和幸存者

IF 0.6

British Journal of Diabetes Pub Date : 2022-12-22 DOI: 10.15277/bjd.2022.353

Hugo Lawrence

引用次数: 0

Impaired awareness of hypoglycaemia 低血糖意识受损

IF 0.6

British Journal of Diabetes Pub Date : 2022-12-22 DOI: 10.15277/bjd.2022.358

S. Amiel

引用次数: 1

Fat – pharmacological therapies 脂肪-药物治疗

IF 0.6

British Journal of Diabetes Pub Date : 2022-12-22 DOI: 10.15277/bjd.2022.367

Stephen C. Bain

引用次数: 0

Insulin – the sharp end of the needle: experiences of 48 years with diabetes 胰岛素——针尖：糖尿病48年的经验

IF 0.6

British Journal of Diabetes Pub Date : 2022-12-22 DOI: 10.15277/bjd.2022.356

H. Alban Davies

引用次数: 1

#We are not waiting - DIY APS Do-It-Yourself Artiﬁcial Pancreas Systems: The story so far #我们没有等待-DIY APS自助式人工胰腺系统：迄今为止的故事

IF 0.6

British Journal of Diabetes Pub Date : 2022-12-22 DOI: 10.15277/bjd.2022.373

T. Crabtree, B. Ryder, E. Wilmot

{"title":"#We are not waiting - DIY APS Do-It-Yourself Artiﬁcial Pancreas Systems: The story so far","authors":"T. Crabtree, B. Ryder, E. Wilmot","doi":"10.15277/bjd.2022.373","DOIUrl":"https://doi.org/10.15277/bjd.2022.373","url":null,"abstract":"Introduction In 2015 Dana Lewis, a person with diabetes, developed her own hybrid-closed loop system and began the #WeAreNotWaiting movement (Figure 1). These systems, often called “do-it-yourself” artificial pancreas systems (DIY APS) or open-source closed-loop automated insulin delivery systems, combine an insulin pump, a sensor and an algorithm to maintain glucose levels in range. Whilst early versions were “hybrid” – in other words they still required manual bolusing-the newer versions of the algorithm have been used as a fully-closed loop (no bolus required!) by some individuals. An article written in 2019 provides further detail on these systems and some of the issues associated with them.1 These systems filled a gap by circumnavigating the approvals that commercial companies require in order to launch similar systems. There are three systems commonly encountered: OpenAPS, AndroidAPS and Loop.1 At the time of writing all three systems are unapproved and unregulated. When these systems first entered UK services the evidence was limited. However, self-reported outcomes from users of the systems were encouraging from both glycaemia and safety points of view.2-4 At that time, the approach taken across UK diabetes services was inconsistent and guidelines from the General Medical Council and others were unclear.5 Work was undertaken to explore the opinions of UK healthcare professionals; initial position statements were produced by Diabetes UK and other organisations to support users of these systems.6,7 We also explored the concerns of individuals with diabetes commencing the use of these systems, and were able to demonstrate that they were less concerned with safety and","PeriodicalId":42951,"journal":{"name":"British Journal of Diabetes","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2022-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45519088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

1993 - The Diabetes Control and Complications Trial (DCCT) 1993年-糖尿病控制和并发症试验（DCCT）

IF 0.6

British Journal of Diabetes Pub Date : 2022-12-22 DOI: 10.15277/bjd.2022.357

B. Ryder

引用次数: 0

Gazing into the future – the next 100 years. Perspectives from diabetologists 展望未来——未来100年。糖尿病学家的观点

IF 0.6

British Journal of Diabetes Pub Date : 2022-12-22 DOI: 10.15277/bjd.2022.399

R. Ryder, E. Wilmot, T. Crabtree

引用次数: 0

Type 2 diabetes: the problem and the solution 2型糖尿病：问题和解决方案

IF 0.6

British Journal of Diabetes Pub Date : 2022-12-22 DOI: 10.15277/bjd.2022.366

Roy Taylor

引用次数: 0

Implementing the new NICE guidelines for type 2 diabetes (NG28): Focusing beyond HbA1c targets and clinically phenotyping patients to the appropriate second-line agent 实施新的2型糖尿病NICE指南（NG28）：关注HbA1c靶点和临床表型患者之外的适当二线药物

IF 0.6

British Journal of Diabetes Pub Date : 2022-12-21 DOI: 10.15277/bjd.2022.385

L. Varadhan, P. Saravanan, Sarah N Ali, W. Hanif, Vinod Patel

{"title":"Implementing the new NICE guidelines for type 2 diabetes (NG28): Focusing beyond HbA1c targets and clinically phenotyping patients to the appropriate second-line agent","authors":"L. Varadhan, P. Saravanan, Sarah N Ali, W. Hanif, Vinod Patel","doi":"10.15277/bjd.2022.385","DOIUrl":"https://doi.org/10.15277/bjd.2022.385","url":null,"abstract":"A signiﬁcant number of cardiovascular outcome trials have been published to support decision-making regarding treatment options after or alongside metformin in people with type 2 diabetes (T2DM), speciﬁcally targeting prevention of adverse cardiovascular and renal outcomes. The latest NICE guidelines recommend the use of sodium-glucose transport inhibitors (SGLT2i) in patients with cardiovascular diseases, heart failure and chronic kidney disease with diabetes and recommends the use of glucagon-like polypeptide receptor agonists (GLP-1RA) only in a selected group of patients. A comprehensive summary of the various trials, structured around patient characteristics and clinical outcomes, can help to compare the various classes of drugs and drugs within the class. Since the drug acquisition cost within a class is generally the same in the UK, the drug with the best available evidence in the class should be chosen to maximise clinical beneﬁt for the patient. Clinical phenotyping, a process of aligning a patient to the inclusion criteria and the desired clinical outcomes of a trial, can guide the choice of the best drug within a class.","PeriodicalId":42951,"journal":{"name":"British Journal of Diabetes","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2022-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49430097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Liraglutide 3.0 (Saxenda) in bariatric patients: a retrospective real-world clinical evaluation of effectiveness 利拉鲁肽3.0（Saxenda）在减肥患者中的疗效回顾性现实世界临床评估

IF 0.6

British Journal of Diabetes Pub Date : 2022-12-21 DOI: 10.15277/bjd.2022.350

Amelia Simenacz, Rebekah Wilmington, C. Green, Arash Ardavani, I. Idris

{"title":"Liraglutide 3.0 (Saxenda) in bariatric patients: a retrospective real-world clinical evaluation of effectiveness","authors":"Amelia Simenacz, Rebekah Wilmington, C. Green, Arash Ardavani, I. Idris","doi":"10.15277/bjd.2022.350","DOIUrl":"https://doi.org/10.15277/bjd.2022.350","url":null,"abstract":"Background: Glucagon-like peptide-1 analogues such as liraglutide 3.0 mg (Saxenda) have yielded signiﬁcant weight loss in clinical trials when combined with lifestyle interventions. Despite the recent approval of liraglutide 3.0 mg, its success among patients attending specialist bariatric units remains uncertain.\u0000Objective: This study investigated the effectiveness of liraglutide 3.0 mg on weight, body mass index (BMI), treatment tolerability and its effects on glycated haemoglobin (HbA1c).\u0000Methods: Clinical data were retrospectively obtained from medical records within Tier 3-4 bariatric weight management clinics. Wilcoxon signed rank tests were employed to establish the statistical signiﬁcance (p<0.05) of changes in weight and HbA1c.\u0000Results: 33 patients were identiﬁed (72.7% female with mean baseline age, weight and BMI of 44.8 years, 156.6 kg and 55.0 kg/m2, respectively). Eighteen patients had completed 26 weeks of treatment. Of the 18 patients, the discontinuation rate due to side effects was 15.2%, indicating substantial treatment tolerance. After 26 weeks of treatment, BMI (±standard deviation) was signiﬁcantly reduced by 7.9±6.3% (p<0.05) and 72.2% of patients achieved at least 5% weight loss. Additionally, a signiﬁcant decrease in median HbA1c (4.5±4.5 mmol/mol) was observed (p<0.05), concurrent with increased remission from prediabetes.\u0000Conclusion: This retrospective study revealed that liraglutide 3.0 mg, together with lifestyle management, reduced weight and improved glycaemic control. These results support liraglutide’s application in certain high-risk populations, including patients waiting for bariatric surgical intervention.","PeriodicalId":42951,"journal":{"name":"British Journal of Diabetes","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2022-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44730492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1